Back

Project Details

Close up of an African woman

MobileOCT

Using smartphones to detect cancer

Project URL: mobileoct.com
Project Twitter: @mobileoct

Organisation Twitter: @MobileOct

  • Community Engagement
  • Health
  • Audiovisual
  • Physical Computing

Cervical cancer is the number one cause of death for women in low-resource settings and leads to 275,000 deaths annually. In many countries the lack of funding and adequate technology limits the amount of screening for cervical cancer taking place.
 
Led by Dr. David Levitz, a biomedical engineer, and Ariel Beery, former CEO of PresenTense, a social startup incubator in Israel, MobileOCT has made significant strides in establishing its value as a potentially game-changing solution to reduce cervical cancer.
 
Integrating a mobile phone, MobileOCT’s mobile colposcope captures high-resolution images of the cervical epithelial tissue and subsequently transmits them to consultants for diagnostic and treatment decision support.

At the core of MobileOCT’s approach are two complementary innovations: powerful collaboration and telehealth features that enable healthcare providers to improve case management and optimize use of healthcare resources, and cutting-edge biomedical optics that aid in more accurate diagnosis of cancer at its earliest stages.
Of their venture, Beery says 'Our mission is to give anyone with access to a mobile phone the ability to save their lives and the lives of people they love.’

The entire set up – case, handle, lens – cuts the cost of a colposcope from $10,000 to $400.  The technology, still in prototype, is in field pilots in Kenya, Botswana, Haiti, Mexico and the USA.

To date, MobileOCT has received preliminary orders for more than 100 first-generation mobile colposcopes with expected delivery in Q1 2015.

Image 'IAEA PACT helps (05810173)' courtesy of IAEA Imagebank

Last updated: 09th of June, 2014

Cookies on the Social Tech Guide

Social Tech Guide uses cookies to provide you with an enhanced user experience. To remove this message, please click continue.

Continue Learn more